2,902 reports of this reaction
3.0% of all CARBIDOPA AND LEVODOPA reports
#5 most reported adverse reaction
DYSKINESIA is the #5 most commonly reported adverse reaction for CARBIDOPA AND LEVODOPA, manufactured by Amneal Pharmaceuticals LLC. There are 2,902 FDA adverse event reports linking CARBIDOPA AND LEVODOPA to DYSKINESIA. This represents approximately 3.0% of all 97,592 adverse event reports for this drug.
Patients taking CARBIDOPA AND LEVODOPA who experience dyskinesia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSKINESIA is a less commonly reported adverse event for CARBIDOPA AND LEVODOPA, but still significant enough to appear in the safety profile.
In addition to dyskinesia, the following adverse reactions have been reported for CARBIDOPA AND LEVODOPA:
The following drugs have also been linked to dyskinesia in FDA adverse event reports:
DYSKINESIA has been reported as an adverse event in 2,902 FDA reports for CARBIDOPA AND LEVODOPA. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSKINESIA accounts for approximately 3.0% of all adverse event reports for CARBIDOPA AND LEVODOPA, making it a notable side effect.
If you experience dyskinesia while taking CARBIDOPA AND LEVODOPA, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.